Bill Haney’s Skyhawk spears another marquee alliance for its work drugging RNA in Takeda neuro pact

Com­ing af­ter its Shire buy­out, Take­da has al­lied with Sky­hawk to dis­cov­er new small mol­e­cules for un­spec­i­fied neu­ro­log­i­cal

Joining forces with Skyhawk, C4 Therapeutics, Biogen buys more shots on goal on SMA, Alzheimer’s

In twin deals an­nounced on Fri­day, Bio­gen $BI­IB is ty­ing up with Sky­hawk Ther­a­peu­tics

The new serial entrepreneur in the biotech arena launches another upstart looking to drug RNA

Af­ter a life­time of en­tre­pre­neur­ship, Bill Haney has dis­cov­ered how much fun it can be to set up new biotechs.

Top 20 Life Science Startups to Watch in 2019

BioSpace is proud to present its NextGen Bio “Class of 2019,” a list of 20 up-and-coming life science companies in North America

Skyhawk Announces Strategic Collaboration with Celgene to Discover and Develop Novel mRNA Splicing

Skyhawk and Celgene enter into a five-year strategic collaboration.

Skyhawk, copying Dragonfly model, gets cash for RNA R&D

Tim Disney—the great-nephew of Walt Disney—is among those who have signed term sheets.

Biogen looks to expand neuro pipeline via C4, Skyhawk deals

A pair of deals announced Friday leaves Biogen Inc. (NASDAQ:BIIB) poised to expand the druggable space of its neurology pipeline. Biogen...

Biotech Celgene inks $60M deal with newcomer Skyhawk to develop RNA drugs for ALS, Huntington’s

Under the deal, Celgene received the exclusive option to license up to five drug candidates born out of Skyhawk’s development platform

Disney, Family Offices Back Second Bio Startup from Tech Entrepreneur Haney

To launch his first biotech startup, Dragonfly Therapeutics, Bill Haney went to private family offices, including one linked to the...